Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gridelli, C, Maione, P, Castaldo, V, Rossi, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394460/
https://www.ncbi.nlm.nih.gov/pubmed/14612886
http://dx.doi.org/10.1038/sj.bjc.6601387
Descripción
Sumario:Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.

Ejemplares similares